Related Experiment Video
Updated: Jun 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Change in serum lipids after acute coronary syndromes: secondary analysis of SPACE ROCKET study data and a
Julian H Barth1, Beryl M Jackson, Amanda J Farrin
1Clinical Biochemistry, Leeds General Infirmary, Leeds, United Kingdom. julian.barth@leedsth.nhs.uk
Insights
Serum cholesterol significantly drops after myocardial infarction (MI). New research shows a 10% decrease in total cholesterol post-MI, highlighting the clinical importance of early lipid level measurement.
Area of Science:
- Cardiology
- Clinical Lipidology
Background:
- Traditional belief: serum cholesterol falls significantly post-myocardial infarction (MI), returning to baseline in ~3 months.
- Recent challenges question the magnitude and clinical significance of this post-MI cholesterol drop.
Purpose of the Study:
- To re-evaluate the extent and clinical relevance of serum lipid changes immediately following acute myocardial infarction (AMI).
- To determine the optimal timing for serum lipid measurement in AMI patients.
Main Methods:
- Analysis of serum lipids from participants in the SPACE ROCKET trial (day 1 vs. days 2-4 post-AMI).
- Comprehensive literature review and meta-analysis of 25 studies reporting absolute lipid changes post-AMI.
Main Results:
- SPACE ROCKET trial: Mean total cholesterol decreased by 0.71 mmol/L (P < 0.0001) between day 1 and days 2-4 post-AMI.
- Meta-analysis: A 9-11% fall in total cholesterol observed 3-14 days post-AMI.
- Meta-analysis: Triglycerides showed an 18% rise from baseline between day 9 and 12 weeks post-AMI.
Conclusions:
- A significant 10% decrease in total cholesterol occurs after AMI, carrying substantial clinical significance.
- Serum lipid measurements in AMI patients are most informative when taken within the initial hours of presentation.
Background:
It has long been an accepted belief that serum cholesterol significantly falls after myocardial infarction and that a return to pre-event levels takes approximately 3 months. The magnitude and clinical significance of this fall has recently been challenged.
Methods:
In the Secondary Prevention of Acute Coronary Events-Reduction Of Cholesterol to Key European Targets (SPACE ROCKET) trial, we measured serum lipids of individuals on day 1 and between days 2 and 4 after acute myocardial infarction (AMI). Second, we performed a thorough literature review and compared all studies reporting data on absolute changes in lipids immediately after AMI, using weighted means.
Results:
Of 1263 SPACE ROCKET participants, 128 had paired lipid measurements where both samples had been measured using identical methods at baseline and on days 2-4 after AMI. The mean lowering in total cholesterol between day 1 and day 2-4 was 0.71 mmol/L (95% CI 0.58-0.84; P < 0.0001) and in triglycerides was 0.10 mmol/L (-0.14-0.33; P = 0.405). A total of 25 papers showing absolute lipid changes post-AMI were identified. The combined data demonstrated a mean fall in total cholesterol of 9% to 11% from baseline over days 3-14 post-AMI, whereas for triglycerides, there was a rise of 18% from baseline to between day 9 and 12 weeks.
Conclusions:
After a secondary analysis of SPACE ROCKET data and a comparison of previously published data, we report a 10% fall in total cholesterol after AMI-a difference that is of high clinical significance. Consequently, measurement of serum lipids in patients with AMI should be performed within the first hours after presentation.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Acute Coronary Syndrome I: Introduction